Pacira's Cryoneurolysis Device Shows Superior Pain Relief Over Radiofrequency Ablation in Chronic Low Back Pain Study
核心洞察
A 12-month pilot study published in Pain Physician demonstrated that Pacira BioSciences (搜索)' iovera° (搜索) cryoneurolysis system provided significantly better pain reduction and functional outcomes compared to radiofrequency ablation (搜索) in chronic low back pain (搜索) patients.
Patients treated with iovera° (搜索) experienced significantly lower pain scores at 180 days (3.1 vs. 5.4, p=0.01) and 360 days (3.0 vs 6.1, p=0.01) compared to radiofrequency ablation (搜索) patients.
The study showed that 45.5% of iovera° (搜索) patients required additional spine injections after 180 days compared to 75% of radiofrequency ablation (搜索) patients, with no treatment-related adverse events reported in either group.
Pacira BioSciences (搜索) announced results from a randomized 30-patient pilot study demonstrating that its iovera° (搜索) cryoneurolysis system provided superior pain relief and functional outcomes compared to radiofrequency ablation (搜索) (RFA) for chronic low back pain (搜索) (CLBP) over a 12-month period. The study, published in Pain Physician, the official journal of the American Society of Interventional Pain Physicians, represents a significant advancement in non-opioid pain management approaches.
Study Design and Patient Population
The unblinded, single-center pilot study evaluated patients with facet-mediated CLBP who were randomized to receive either iovera° (搜索) cryoneurolysis or RFA. Baseline characteristics, including pain scores, BMI, pain duration, and disability were similar between groups. The study addresses a critical medical need, as CLBP is the leading cause of disability in the U.S. and a major driver of opioid use, with facet-mediated pain (搜索) representing up to 45% of cases.
Superior Pain Reduction Outcomes
Patients treated with iovera° (搜索) experienced significantly lower pain scores at both 180 and 360 days compared with those treated with RFA. At day 180, pain scores were 3.1 versus 5.4 (p=0.01), and at day 360, scores were 3.0 versus 6.1 (p=0.01). These statistically significant differences demonstrate sustained pain relief advantages of the cryoneurolysis approach.
Improved Functional Disability Scores
Functional disability improved more substantially with iovera° (搜索), with Oswestry Disability Index (ODI) scores significantly lower at 360 days. The ODI scores at day 360 were 10.1 versus 20.6 (p=0.002), indicating meaningful improvements in patients' ability to perform daily activities.
Reduced Need for Additional Treatments
The study revealed that fewer iovera° (搜索) patients required additional spine injections after 180 days, with 45.5% of iovera° patients versus 75% of RFA patients needing additional treatments. This reduction in repeat interventions suggests more durable pain relief with the cryoneurolysis approach.
Safety Profile
No treatment-related adverse events were reported in either group across the 12-month follow-up period, demonstrating the favorable safety profile of both treatments. The study noted limitations including its unblinded design and the restriction of the cryoneurolysis device's short tip to patients with low body mass indexes.
Technology and Mechanism
The iovera° (搜索) system uses the body's natural response to cold to treat peripheral nerves (搜索) and immediately reduce pain without the use of drugs. The device applies targeted cold to a peripheral nerve, creating a precise cold zone under the skin that is cold enough to immediately prevent the nerve from sending pain signals without causing damage to surrounding structures. The effect is immediate and can last up to 90 days as the nerve gradually regenerates.
Clinical Significance and Future Development
"These published findings highlight the potential of iovera° (搜索) to offer immediate, sustained and meaningful pain relief without the disadvantages of radiofrequency ablation (搜索)," said Jonathan Slonin, M.D., MBA, Chief Medical Officer at Pacira BioSciences (搜索). "With chronic low back pain (搜索) contributing to disability, opioid prescriptions, and significant economic burden, we are encouraged by these data and how they support our ongoing spine tip development program."
The results support ongoing collaborative initiatives to expand the clinical evidence for iovera° (搜索) across spine-related pain pathways. A new SmartTip to allow deeper nerve access for lumbar applications was recently cleared by the FDA, addressing one of the current limitations identified in the study.
RFA, a standard interventional treatment, uses heat to destroy targeted nerves but can damage nearby tissue, underscoring the need for alternative, tissue-sparing approaches like cryoneurolysis. The iovera° (搜索) system offers a drug-free alternative that provides immediate pain relief without the tissue damage associated with heat-based treatments.